Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
Results of well-controlled prospective clinical trials showed the efficacy of lipid-lowering therapies in the reduction of cardiovascular (CV) events in western populations, but they were not reported with a Chinese population. This multicenter study was conducted to determine the effects of Xuezhikang (XZK), a partially purified extract of red yeast rice, on lipoprotein and CV end points in Chinese patients who experienced a previous myocardial infarction. Nearly 5,000 of these patients with average low-density lipoprotein cholesterol levels at baseline were randomly assigned either to placebo or to XZK daily for an average of 4.5 years. The primary end point was a major coronary event that included nonfatal myocardial infarction and death from coronary heart disease. Frequencies of the primary end point were 10.4% in the placebo group and 5.7% in the XZK-treated group, with absolute and relative decreases of 4.7% and 45%, respectively. Treatment with XZK also significantly decreased CV and total mortality by 30% and 33%, the need for coronary revascularization by 1/3, and lowered total and low-density lipoprotein cholesterol and triglycerides, but raised high-density lipoprotein cholesterol levels. In conclusion, long-term therapy with XZK significantly decreased the recurrence of coronary events and the occurrence of new CV events and deaths, improved lipoprotein regulation, and was safe and well tolerated.
Lu
Zongliang
Z
Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, Peoples Republic of China.
Kou
Wenrong
W
Du
Baomin
B
Wu
Yangfeng
Y
Zhao
Shuiping
S
Brusco
Osvaldo A
OA
Morgan
John M
JM
Capuzzi
David M
DM
Li
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000494:pharmacology*; D002681:China / Q000453:epidemiology; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D019587:Dietary Supplements; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009017:Morbidity / Q000639:trends; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control*; D011446:Prospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome
D001688:Biological Products; D008078:Cholesterol, LDL; D004365:Drugs, Chinese Herbal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C117343:red yeast rice; C496822:xuezhikang